MFG
CASI icon

Mendota Financial Group’s CASI Pharmaceuticals CASI Stock Holding History

Mendota Financial Group’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20
Closed -$73 – 393
2024
Q1 		$73 Buy
+20
New +$108 ﹤0.01% 323

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mendota Financial Group's CASI Position: Q2 2024 in Review

Mendota Financial Group sold out of CASI Pharmaceuticals (CASI) in Q2 2024, closing a stake of 20 shares — an estimated $73 sold.

Mendota Financial Group first reported a position in CASI in Q1 2024 and held it in 1 quarter. The position peaked at $73 in Q1 2024. 23 funds tracked by Wall St. Rank hold CASI as of Q2 2024.

  • Mendota Financial Group reported no remaining CASI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Mendota Financial Group sold 20 CASI Pharmaceuticals shares in Q2 2024, an estimated $73.
  • Mendota Financial Group first reported a position in CASI Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Mendota Financial Group's CASI Pharmaceuticals position peaked at $73 in Q1 2024.
  • 23 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2024.

Based on Mendota Financial Group's 13F filing for Q2 2024, filed 11 Jul 2024.